“Our science strongly suggests that ENU200, a repurposed drug with a well-established clinical and safety profile, has the potential to be a broad solution to address the COVID-19 pandemic and, specifically, the near 80 percent of coronavirus cases that are asymptomatic, mild to moderate,” said Harrison.
In a statement posted on the company’s website on Monday, April 27, Harrison noted that the rationale for developing ENU200 arose from a bioinformatic search for in-silico identification of prior-approved chemical compounds blocking the CoV proteins, spike S glycoprotein and Mpro.
The results suggest the use of ENU200 as a current, viable treatment for COVID-19 and other CoV infections, Harrison stated.
Since ENU200 has a well-tolerated safety profile, Ennaid is confident that being allowed to treat the up to 80 percent asymptomatic, mild/moderate cases of COVID-19 infections will reduce COVID-19 viral shedding and severity, Harrison noted.
Ennaid believes it can quickly bring ENU200 to market by treating patients with COVID-19 in a Phase 3 in-home, self-dosing clinical trial of patients with asymptomatic, mild to moderate coronavirus infections utilizing their iClickCare®️ secure clinical reporting software service to monitor the in-home trials.
